Saturday, December 13, 2008
Kidney Stones - Useful Treatments For the Sufferers of Kidney Stones
Kidney stones treatment can typically be run with no surgical procedure. Drinking water is the most essential point in assisting to cut growth. Treatment for it is important for a sufferer. Those who have never passed a kidney stone may not realize the seriousness of the symptoms. There is not a lot a person can execute with unbearable pain other than seek emergency care. If this is the initial incident and no prior diagnosis has been established, it is significant to be observed by a physician.
Potential For Early Cancer Diagnosis Technique
A team led by a Northwestern University biomedical engineer has developed a new optical technique that holds promise for minimally invasive screening methods for the early diagnosis of cancer. The researchers have shown for the first time that nanoscale changes are present in cells extremely early on in carcinogenesis. Continue reading ...
The International Agency for Research on Cancer (IARC), a division of the World Health Organization (WHO), has released updated cancer death projections in a call to action, asking the government to help fund cancer prevention and research initiatives and international tobacco control policies. According to the report, the burden of cancer doubled globally between 1975 and 2000, and cancer is expected to become the leading cause of death worldwide in 2010. Continue reading ...
"Young men undergoing treatment for cancer often want to know how the disease and its treatment affect their chances of fathering healthy children. Our large-scale study shows that there is a slightly higher risk of deformities, but the actual risk of having a child with deformities is nevertheless extremely low. I think this is good news!" These words are from the cancer physician Olof Stahl, who has studied this issue in his coming dissertation from Lund University in Sweden. Continue reading ...
Dr. De Yang, Senior Scientist of the Cellular Immunology Group at the National Cancer Institute of the National Institutes of Health will present at the 7th Cytokines and Inflammation Conference on January 29-30, 2009 in San Diego, CA. Dr. Yang from the NCI will give a presentation on "Alarmin Regulation of Inflammation and Immunity" on January 30, 2009 at 8:45 on the second morning of the conference. Dr. Continue reading ...
SAN ANTONIO - Investigators are reporting favorable early results using RAD001 (Afinitor) combined with weekly paclitaxel and trastuzumab to treat patients with HER-2 overexpressing metastatic breast cancer who have demonstrated prior resistance to trastuzumab. The results, released here at the 2008 San Antonio Breast Cancer Symposium (SABCS), show that RAD001 combined with trastuzumab and chemotherapy halted tumor growth in 77 percent of patients. Continue reading ...
Michael Karin, Professor of Pharmacology Tumor Growth Invasion and Metastasis at UCSD to Give Keynote Speech at GTCbio's 7th Cytokines and Inflammation Conference on January 29-30, 2009 in San Diego, CA Dr. Continue reading ...
The International Agency for Research on Cancer (IARC), a division of the World Health Organization (WHO), has released updated cancer death projections in a call to action, asking the government to help fund cancer prevention and research initiatives and international tobacco control policies. According to the report, the burden of cancer doubled globally between 1975 and 2000, and cancer is expected to become the leading cause of death worldwide in 2010. Continue reading ...
"Young men undergoing treatment for cancer often want to know how the disease and its treatment affect their chances of fathering healthy children. Our large-scale study shows that there is a slightly higher risk of deformities, but the actual risk of having a child with deformities is nevertheless extremely low. I think this is good news!" These words are from the cancer physician Olof Stahl, who has studied this issue in his coming dissertation from Lund University in Sweden. Continue reading ...
Dr. De Yang, Senior Scientist of the Cellular Immunology Group at the National Cancer Institute of the National Institutes of Health will present at the 7th Cytokines and Inflammation Conference on January 29-30, 2009 in San Diego, CA. Dr. Yang from the NCI will give a presentation on "Alarmin Regulation of Inflammation and Immunity" on January 30, 2009 at 8:45 on the second morning of the conference. Dr. Continue reading ...
SAN ANTONIO - Investigators are reporting favorable early results using RAD001 (Afinitor) combined with weekly paclitaxel and trastuzumab to treat patients with HER-2 overexpressing metastatic breast cancer who have demonstrated prior resistance to trastuzumab. The results, released here at the 2008 San Antonio Breast Cancer Symposium (SABCS), show that RAD001 combined with trastuzumab and chemotherapy halted tumor growth in 77 percent of patients. Continue reading ...
Michael Karin, Professor of Pharmacology Tumor Growth Invasion and Metastasis at UCSD to Give Keynote Speech at GTCbio's 7th Cytokines and Inflammation Conference on January 29-30, 2009 in San Diego, CA Dr. Continue reading ...
Friday, December 12, 2008
Breast Cancer - AstraZeneca's Response To Letrozole Datapresented At San Antonio Breast Cancer Symposium (SABCS), 11 -14 December 2008
AstraZeneca is pleased to see additional data presented at SABCS reinforce that there is no evidence that a sequencing strategy is superior to a 5 year aromatase inhibitor (AIs) strategy. AstraZeneca believes that AIs should be used upfront in all newly diagnosed breast cancer postmenopausal women as it is critical to keep patients cancer free for as long as possible. Complete news at...
Dr. Samir Hanash, Program Head at the Fred Hutchinson Cancer Research Center in Seattle, WA will give the keynote address on the discovery and development of biomarkers at the 2nd annual Oncology Biomarkers Conference on January 19-20, 2009 in Miami, Florida. Dr. Complete news at...
Intercell AG (VSE: ICLL) announced the execution of a contract modification with the U.S. Department of Health and Human Services (HHS). The agreement commits additional funding of USD 12.5 m for Intercell's Pandemic Influenza program. Intercell is developing a Pandemic Influenza Vaccine Patch System that includes an immunostimulant patch administered in conjunction with an injected Pandemic Influenza vaccine (manufactured by Solvay Biologicals, B.V. Complete news at...
In a new tactic in the fight against cancer, Cornell University researcher Michael King has developed what he calls a lethal "lint brush" for the blood -- a tiny, implantable device that captures and kills cancer cells in the bloodstream before they spread through the body. Complete news at...
Vical Incorporated (Nasdaq: VICL) announced that the company's Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial. The company previously reported that the vaccines had achieved potentially protective levels of antibody responses in up to 67% of evaluable subjects in the trial's higher dose cohorts. Complete news at...
Douglas Easton, Ph.D., whose international studies in breast cancer explained the genetic patterns and causes of the BRCA1 and BRCA2 gene mutations which indicate a person's risk for breast cancer, has been selected to receive the inaugural American Association for Cancer Research (AACR) Outstanding Investigator Award in Breast Cancer Research. This award, funded by Susan G. Complete news at...
Dr. Samir Hanash, Program Head at the Fred Hutchinson Cancer Research Center in Seattle, WA will give the keynote address on the discovery and development of biomarkers at the 2nd annual Oncology Biomarkers Conference on January 19-20, 2009 in Miami, Florida. Dr. Complete news at...
Intercell AG (VSE: ICLL) announced the execution of a contract modification with the U.S. Department of Health and Human Services (HHS). The agreement commits additional funding of USD 12.5 m for Intercell's Pandemic Influenza program. Intercell is developing a Pandemic Influenza Vaccine Patch System that includes an immunostimulant patch administered in conjunction with an injected Pandemic Influenza vaccine (manufactured by Solvay Biologicals, B.V. Complete news at...
In a new tactic in the fight against cancer, Cornell University researcher Michael King has developed what he calls a lethal "lint brush" for the blood -- a tiny, implantable device that captures and kills cancer cells in the bloodstream before they spread through the body. Complete news at...
Vical Incorporated (Nasdaq: VICL) announced that the company's Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial. The company previously reported that the vaccines had achieved potentially protective levels of antibody responses in up to 67% of evaluable subjects in the trial's higher dose cohorts. Complete news at...
Douglas Easton, Ph.D., whose international studies in breast cancer explained the genetic patterns and causes of the BRCA1 and BRCA2 gene mutations which indicate a person's risk for breast cancer, has been selected to receive the inaugural American Association for Cancer Research (AACR) Outstanding Investigator Award in Breast Cancer Research. This award, funded by Susan G. Complete news at...
Subscribe to:
Posts (Atom)
